Amgen shares rose 1.97% in the latest session, according to the supplied headline and market data.
The shares gained despite a market slip, as noted in the October 29 end-of-day headline. The supplied data shows a 1.97% daily gain and a closing price of US$460.73. It does not identify a company-specific announcement behind the move.
Investor takeaway: The headline reports Amgen’s share gain but does not explain what drove it.
Amgen Inc
AMGN.US
AMGN.US
Amgen Inc
WealthAwesomeMarket cap
$244.27B
P/E
28.1x
Div. yield
2.19%
Div. / share
$9.80
52W high
$468.27
52W low
$284.24
1W change
+3.01%
Beta
0.41
Analyst Price Targets
Based on 34 analysts covering AMGN · as of Oct 28, 2026
Wall Street analysts forecast AMGN stock price to fall 13.8% over the next 12 months.
Consensus
Hold3.35 / 5.00
Avg. Target
C$397.32
-13.8% Upside
Previously C$396.70 on Oct 26, 2026
Current Price
C$460.73
Last close
Analyst Breakdown (34 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on AMGN's historical volatility
30-Day Vol
27.5%
Annualized
90-Day Vol
31.9%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$550.81
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$488.99 | C$444.67 – C$537.73 |
| 60 trading days | C$518.98 | C$453.73 – C$593.61 |
| 90 trading days | C$550.81 | C$467.23 – C$649.33 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Amgen closed at US$460.73
The closing price was 96% of the supplied 52-week range, from US$284.24 to US$468.27.
Bull case
Amgen gained 1.97% for the day, and trading volume was 1.15 times its 20-day average.
Bear case
The available information does not explain what drove the gain. The session headline reports the move but offers no cause.
What happened: Amgen rose despite a market slip
The October 29 end-of-day headline says Amgen shares rose despite a market slip. The supplied data shows a 1.97% daily gain and a close of US$460.73. It does not say which market measure fell or point to a company announcement, product update, or other event behind Amgen’s gain. The headline confirms the reported move, but not its cause. See the Amgen stock page for listing details.
What the numbers show: above-average trading volume
Amgen traded 2,950,741 shares, compared with a 20-day average of 2,600,965. That’s 1.15 times the average. The stock also rose 3.01% over one week, 8.76% over one month, and 43.50% year to date. Its US$460.73 close was within the supplied 52-week range of US$284.24 to US$468.27, at 96% of the range. These figures show price and trading activity, but they don’t explain why the shares moved.
What to watch next: a stated catalyst, if one emerges
The supplied facts don’t link the gain to a specific company development. A separate October 29 headline previews Amgen’s third-quarter earnings, while an October 28 headline says the company announced a webcast of its 2026 third-quarter financial results. Neither item shows that earnings news caused the share gain. Later company disclosures or results could add context, but no results or webcast details are included here. See the Amgen listing and analyst-ratings page for reference. The supplied information does not explain the reported move.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
